Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab Says CD47 Inhibitor Effective in Myelodysplastic Syndrome

publication date: Sep 12, 2022

I-Mab reported its novel CD47 inhibitor showed encouraging results in a China Phase II trial data in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS). Lemzoparlimab was administered in combination with azacitidine (AZA). After six months of treatment, the overall response rate was 87% and complete response rate was 40%. After four months of treatment, the efficacy was nearly as high. I-Mab, a Shanghai-Maryland biopharma, plans to conduct a randomized Phase III trial of the candidate in the same patient population. Lemzoparlimab is one of four I-Mab candidates in Phase II trials. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital